At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 6,102 enrolled
Drug / intervention
mRNA-1010 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Stratified, Observer-blind, Active-Controlled Study to Evaluate the Immunogenicity and Safety of mRNA-1010 Seasonal Influenza Vaccine in Adults 18 Years and Older
In Brief
A Phase 3 clinical trial evaluating mRNA-1010 and Fluarix Tetra for Seasonal Influenza. Completed, enrolled 6,102 participants across 53 sites in 5 countries.
Detailed Summary
The primary objectives of this study are to evaluate the humoral immunogenicity of mRNA-1010 relative to that of an active comparator against vaccine-matched influenza A and B strains at Day 29, and to evaluate the safety and reactogenicity of mRNA-1010.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeasonal Influenza
CountriesArgentina, Australia, Colombia, Panama, Philippines
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
Enrollment StartJun 2022
First PostedJun 2022
Primary CompletionSep 2023
TodayJul 2026
First PostedJun 13, 2022
Enrollment StartJun 6, 2022
Primary CompletionSep 4, 2023
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 4.1 years ago
Interventions
mRNA-1010biological
Sterile liquid for injection
Fluarix Tetrabiological
Sterile suspension for injection